Franklin Biotechnology Discovery Fund Class R6 (FRBRX)

Fund Assets	1.42B
Expense Ratio	0.69%
Min. Investment	$1,000,000
Turnover	n/a
Dividend (ttm)	11.76
Dividend Yield	10.07%
Dividend Growth	n/a
Payout Frequency	n/a
Ex-Dividend Date	Dec 20, 2024

Previous Close	114.82
YTD Return	-9.62%
1-Year Return	-5.43%
5-Year Return	-5.18%
52-Week Low	106.70
52-Week High	162.76
Beta (5Y)	n/a
Holdings	89
Inception Date	May 1, 2013

About FRBRX

The Franklin Biotechnology Discovery Fund Class R6 (FRBRX) seeks to provide capital appreciation. Under normal market conditions, the Fund predominantly invests in equity securities and invests at least 80% of its net assets in securities of biotechnology companies(at least 50% of its earnings derived from biotechnology activities) and discovery research firms.

• Category: Health
• Stock Exchange: NASDAQ
• Ticker Symbol: FRBRX
• Share Class: Class R6
• Index: NASDAQ Biotechnology CR

Performance

FRBRX had a total return of -5.43% in the past year, including dividends. Since the fund's inception, the average annual return has been 5.78%.

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol	Share Class	Expense Ratio
FTDZX	Advisor Class	0.80%
FBDIX	Class A	1.05%
FBTDX	Class C	1.80%

Top 10 Holdings

49.67% of assets

Name	Symbol	Weight
Vertex Pharmaceuticals Incorporated	VRTX	7.98%
Gilead Sciences, Inc.	GILD	7.55%
Amgen Inc.	AMGN	7.37%
Regeneron Pharmaceuticals, Inc.	REGN	5.06%
Ascendis Pharma A/S	ASND	4.89%
argenx SE	ARGX	4.08%
Jazz Pharmaceuticals plc	JAZZ	3.92%
Merus N.V.	MRUS	3.21%
PTC Therapeutics, Inc.	PTCT	3.10%
Institutional Fiduciary Trust - Money Market Portfolio	INFXX	2.50%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 20, 2024	$11.7607	Dec 20, 2024
Dec 20, 2022	$0.5857	Dec 20, 2022
Dec 15, 2021	$18.2831	Dec 15, 2021
Dec 15, 2020	$10.3921	Dec 15, 2020
Dec 16, 2019	$14.1643	Dec 18, 2019
Dec 17, 2018	$4.5496	Dec 19, 2018